Crossmark

Empagliflozin improves renal injury of diabetic nephropathy complicated with hyperuricemia through AMPK by promoting autophagy and inhibiting apoptosis

Crossref DOI link: https://doi.org/10.1007/s44446-025-00054-y

Published Online: 2026-01-13

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Zhiqin

Xu, Yanmei

Xu, Chuanwen

Gao, Qi

Wu, Xiaoyan

Wu, Ting
Funding

Funding for this research was provided by:

Clinical Research Project for Wu Jieping Medical Foundation (320.6750.19089-58)

Research Fund from Medical Sci-Tech Innovation Platform of Zhongnan Hospital, Wuhan University (PTXM2020028)
License Information

Text and Data Mining valid from 2026-01-13

Version of Record valid from 2026-01-13
More Information

Article History

Received: 8 April 2025

Accepted: 19 November 2025

First Online: 13 January 2026

Declarations

:

: This experimental scheme was approved by the Medical Ethics Committee of Central South Hospital of Wuhan University (ethics approval numbers 2020142 and ZN2021021), and all subjects provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki.

: The authors declare that they have no competing interests.

: Not applicable.

Document is current

Any future updates will be listed below